BackBio-Rad Laboratories Overview
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Bio-Rad Laboratories Target Price

Analysts' average 12-month price target for Bio-Rad Laboratories is $340.

Get informed when a big investor buys or sells

+ Follow

Share Price

$390.34

Average Target Price

$336.0013.9% downside

5 analysts in the last 4 months

High: $390 | Low: $290

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07RBC Capital$3900.1% downsideOpen
2026-08-05RBC Capital$3705.2% downsideOpen
2026-05-25Wells Fargo$31020.6% downsideOpen
2026-05-14RBC Capital$32018% downsideOpen
2026-05-01Wells Fargo$29025.7% downsideOpen
2026-02-16Wells FargoBrandon Couillard$32018% downsideOpen
2026-02-13UBS$33514.2% downsideOpen
2025-10-30Wells Fargo$34012.9% downsideOpen
2024-10-01CitigroupPatrick Donnelly$4002.5% upsideOpen
2022-12-07RBC Capital$56544.7% upsideOpen

Bio-Rad Laboratories (BIO) FAQ

Bio-Rad Laboratories's target price stands at $340. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $340 for BIO implies 13.9% downside versus today's price ($390.34). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Bio-Rad Laboratories's target price evolved across reporting periods, while the comparison chart places BIO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Bio-Rad Laboratories's reading of $340 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.